OncoMatch

OncoMatch/Clinical Trials/NCT02064673

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

Is NCT02064673 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Curcumin for prostate cancer.

Phase 3Recruitingyair lotanNCT02064673Data as of Jun 2026

Treatment: CurcuminThis is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Curcumin

Cancer type

Prostate Cancer

Disease stage

Required: Stage PT1, PT2, PT3

Grade: Gleason 6Gleason 7 (Gleason)

pathologically confirmed T1-T3 disease; pT1-pT3pNxMx; This includes patients with Gleason 6 or 7(T2 disease)

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages 30–80
Male only

Prior therapy

Must have received: radical prostatectomy

Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate

Cannot have received: hormone therapy

hormone therapy before surgery

Cannot have received: radiation therapy

radiation therapy as primary treatment after surgery

Lab requirements

Blood counts

ANC ≥ 1.5 x 10^3/uL, platelets ≥ 50 x K/uLL, hemoglobin ≥ 10 g/dL

Kidney function

serum creatinine <2mg/dl

Liver function

bilirubin ≤ 1.5 mg/dl; AST/ALT < 2x ULN

adequate renal and liver function as well as bone marrow reserve (measured serum creatinine <2mg/dl, bilirubin ≤ 1.5 mg/dl, ANC ≥ 1.5 x 10 (3) uL, platelets ≥ 50 x K/uLL, and hemoglobin ≥ 10 g/dL); AST/ALT are equal or greater than 2 times the upper limit of normal [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • UT Southwestern Medical Center · Dallas, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT02064673 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior hormone therapy, radiation therapy disqualifies patients from enrollment.

What disease stage is eligible?

Stage PT1 or PT2 or PT3 is required.

Is there an age limit?

Yes. Patients must be 80 years or younger and at least 30 years old.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify